APA (7th ed.) Citation

Goebeler, M., Bata‐Csörgő, Z., De Simone, C., Didona, B., Remenyik, E., Reznichenko, N., . . . Joly, P. (2022). Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: A phase II multicentre, open‐label feasibility trial. British journal of dermatology (1951), 186(3), 429-439. https://doi.org/10.1111/bjd.20782

Chicago Style (17th ed.) Citation

Goebeler, M., et al. "Treatment of Pemphigus Vulgaris and Foliaceus with Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open‐label Feasibility Trial." British Journal of Dermatology (1951) 186, no. 3 (2022): 429-439. https://doi.org/10.1111/bjd.20782.

MLA (9th ed.) Citation

Goebeler, M., et al. "Treatment of Pemphigus Vulgaris and Foliaceus with Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open‐label Feasibility Trial." British Journal of Dermatology (1951), vol. 186, no. 3, 2022, pp. 429-439, https://doi.org/10.1111/bjd.20782.